WO2010007046A3 - Heteroaryl derivatives as dgat1 inhibitors - Google Patents

Heteroaryl derivatives as dgat1 inhibitors Download PDF

Info

Publication number
WO2010007046A3
WO2010007046A3 PCT/EP2009/058960 EP2009058960W WO2010007046A3 WO 2010007046 A3 WO2010007046 A3 WO 2010007046A3 EP 2009058960 W EP2009058960 W EP 2009058960W WO 2010007046 A3 WO2010007046 A3 WO 2010007046A3
Authority
WO
WIPO (PCT)
Prior art keywords
heteroaryl derivatives
dgat1 inhibitors
disorders
dgat1
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2009/058960
Other languages
French (fr)
Other versions
WO2010007046A2 (en
Inventor
Cornelia Jutta Forster
Young-Shin Kwak
Katsumasa Nakajima
Bing Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41136646&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2010007046(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to NZ590285A priority Critical patent/NZ590285A/en
Priority to EA201100189A priority patent/EA201100189A1/en
Priority to AU2009272826A priority patent/AU2009272826A1/en
Priority to BRPI0916216A priority patent/BRPI0916216A2/en
Priority to JP2011517900A priority patent/JP5401544B2/en
Priority to EP09780542A priority patent/EP2349484A2/en
Application filed by Novartis AG filed Critical Novartis AG
Priority to CN200980131154.1A priority patent/CN102119047B/en
Priority to MX2011000628A priority patent/MX2011000628A/en
Priority to CA2731097A priority patent/CA2731097A1/en
Publication of WO2010007046A2 publication Critical patent/WO2010007046A2/en
Publication of WO2010007046A3 publication Critical patent/WO2010007046A3/en
Priority to IL210292A priority patent/IL210292A0/en
Priority to TNP2010000608A priority patent/TN2010000608A1/en
Anticipated expiration legal-status Critical
Priority to MA33609A priority patent/MA32558B1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to compounds of formula (I): where A is an optionally substituted heteroaryl, useful for treating disorders mediated by acyl coA- diacylglycerol acyl transferase 1 (DGAT1), e.g. metabolic disorders. The invention also provides methods of treating such disorders, and compounds and compositions etc. for their treatment.
PCT/EP2009/058960 2008-07-15 2009-07-14 Organic compounds Ceased WO2010007046A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
MX2011000628A MX2011000628A (en) 2008-07-15 2009-07-14 Heteroaryl derivatives as dgat1 inhibitors.
CN200980131154.1A CN102119047B (en) 2008-07-15 2009-07-14 Heteroaryl derivatives as DGAT1 inhibitors
EA201100189A EA201100189A1 (en) 2008-07-15 2009-07-14 Heteroaryl Derivatives As DGAT1 Inhibitors
AU2009272826A AU2009272826A1 (en) 2008-07-15 2009-07-14 Heteroaryl derivatives as DGAT1 inhibitors
BRPI0916216A BRPI0916216A2 (en) 2008-07-15 2009-07-14 organic compost
JP2011517900A JP5401544B2 (en) 2008-07-15 2009-07-14 Heteroaryl derivatives as DGAT1 inhibitors
EP09780542A EP2349484A2 (en) 2008-07-15 2009-07-14 Heteroaryl derivatives as dgat1 inhibitors
NZ590285A NZ590285A (en) 2008-07-15 2009-07-14 Heteroaryl derivatives as dgat1 inhibitors
CA2731097A CA2731097A1 (en) 2008-07-15 2009-07-14 Organic compounds
TNP2010000608A TN2010000608A1 (en) 2009-07-14 2010-12-27 Heteroaryl derivatives as dgat1 inhibitors
IL210292A IL210292A0 (en) 2008-07-15 2010-12-27 Heteroaryl derivatives as dgat1 inhibitors
MA33609A MA32558B1 (en) 2008-07-15 2011-02-11 Organic compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8091308P 2008-07-15 2008-07-15
US61/080,913 2008-07-15

Publications (2)

Publication Number Publication Date
WO2010007046A2 WO2010007046A2 (en) 2010-01-21
WO2010007046A3 true WO2010007046A3 (en) 2010-07-22

Family

ID=41136646

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/058960 Ceased WO2010007046A2 (en) 2008-07-15 2009-07-14 Organic compounds

Country Status (23)

Country Link
US (1) US8703761B2 (en)
EP (4) EP2349484A2 (en)
JP (1) JP5401544B2 (en)
KR (1) KR20110028661A (en)
CN (1) CN102119047B (en)
AR (1) AR072559A1 (en)
AU (1) AU2009272826A1 (en)
BR (1) BRPI0916216A2 (en)
CA (1) CA2731097A1 (en)
CL (1) CL2011000087A1 (en)
CO (1) CO6341581A2 (en)
CR (1) CR20110013A (en)
EA (1) EA201100189A1 (en)
EC (1) ECSP11010830A (en)
IL (1) IL210292A0 (en)
MA (1) MA32558B1 (en)
MX (1) MX2011000628A (en)
NZ (1) NZ590285A (en)
PE (1) PE20110105A1 (en)
SV (1) SV2011003809A (en)
TW (1) TW201006832A (en)
UY (1) UY31986A (en)
WO (1) WO2010007046A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10988462B2 (en) 2018-04-04 2021-04-27 Japan Tobacco Inc. Pyrazole compounds substituted with heteroaryl and pharmaceutical use thereof
US11014910B2 (en) 2018-03-01 2021-05-25 Japan Tobacco Inc. Methyllactam ring compound and pharmaceutical use thereof

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR066169A1 (en) * 2007-09-28 2009-07-29 Novartis Ag DERIVATIVES OF BENZO-IMIDAZOLES, USEFUL FOR DISORDERS ASSOCIATED WITH THE ACTIVITY OF DGAT
JP2011529072A (en) * 2008-07-24 2011-12-01 セラヴァンス， インコーポレーテッド Dual action antihypertensive
JP2012517997A (en) * 2009-02-17 2012-08-09 Ｍｓｄ株式会社 1,4-benzodiazepin-2-one derivatives
JP6099753B2 (en) * 2012-10-03 2017-03-22 アドビナス セラピューティクス リミテッド Spirocyclic compound, composition thereof and pharmaceutical application thereof
WO2017007756A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc Hetero-halo inhibitors of histone deacetylase
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
WO2017087885A1 (en) 2015-11-19 2017-05-26 Dana-Farber Cancer Institute, Inc. Methods of identifying compounds that interfere with erg-driven misguidance of baf complexes in tmprss2-erg driven prostate cancers
TWI691486B (en) 2016-01-29 2020-04-21 日商東麗股份有限公司 Cyclic amine derivatives and pharmaceutical use thereof
HUE057849T2 (en) 2017-01-11 2022-06-28 Alkermes Inc Bicyclic inhibitors of histone deacetylase
US10881649B2 (en) 2017-07-27 2021-01-05 Toray Industries, Inc. Therapeutic agent or preventive agent for alopecia areata
LT3664802T (en) 2017-08-07 2022-06-27 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
US11497752B2 (en) * 2018-01-30 2022-11-15 Foghorn Therapeutics Inc. Compounds and uses thereof
US12172108B2 (en) 2018-08-16 2024-12-24 Emd Millipore Corporation Closed bioprocessing device
WO2020081588A1 (en) 2018-10-17 2020-04-23 Dana-Farber Cancer Institute, Inc. Swi/snf family chromatin remodeling complexes and uses thereof
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN113645971B (en) * 2019-01-29 2024-10-18 福宏治疗公司 Compounds and uses thereof
US12384776B2 (en) 2019-01-29 2025-08-12 Foghorn Therapeutics Inc. Compounds and uses thereof
US12509453B2 (en) 2019-01-29 2025-12-30 Foghorn Therapeutics Inc. BRM/BRG1 inhibitors and uses thereof
CN115484948A (en) * 2020-01-29 2022-12-16 福宏治疗公司 Compounds and their uses
JP7693688B2 (en) * 2020-01-29 2025-06-17 フォグホーン セラピューティクス インコーポレイテッド Compounds and their uses
AU2021213811A1 (en) 2020-01-29 2022-07-28 Foghorn Therapeutics Inc. Compounds and uses thereof
US12383555B2 (en) 2020-05-20 2025-08-12 Foghorn Therapeutics Inc. Methods of treating cancers
WO2022087146A1 (en) 2020-10-22 2022-04-28 Landos Biopharma, Inc. Lancl ligands
US12606553B2 (en) 2021-03-09 2026-04-21 Foghorn Therapeutics Inc. Crystalline forms, compositions containing same, and methods of their use
WO2023111996A1 (en) 2021-12-17 2023-06-22 Reglagene Holding, Inc. Compositions and methods of making and using small molecules in the treatment of cancer
TWD226926S (en) 2022-09-21 2023-08-11 精誠軟體服務股份有限公司 Graphical user interface with changing appearance for computer program
TWD226927S (en) 2022-09-21 2023-08-11 精誠軟體服務股份有限公司 Graphical user interface with changing appearance for computer program
US12215102B2 (en) 2023-02-28 2025-02-04 Reglagene, Inc. Compositions and methods for making and using small molecules for tubulin-targeted therapy in the treatment of cancers and related conditions
WO2024191268A1 (en) * 2023-03-15 2024-09-19 현대약품 주식회사 Novel compound and pharmaceutical composition comprising same
KR20260037054A (en) * 2024-09-09 2026-03-17 현대약품 주식회사 Novel compounds, and pharmaceutical composition comprising the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005206492A (en) * 2004-01-21 2005-08-04 Sankyo Co Ltd Sulfonamide compound
US20070123504A1 (en) * 2005-11-28 2007-05-31 Bolin David R Diacylglycerol acyltransferase inhibitors

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1526938A (en) * 1974-12-19 1978-10-04 Shell Int Research Derivatives of n-phenyl-n-aroylalanine and herbicidal compositions containing them
CA1160234A (en) * 1980-10-30 1984-01-10 Masahiko Nagakura Thiadiazole derivatives and process for preparing same
DE69523182T2 (en) * 1995-06-06 2002-02-07 Pfizer SUBSTITUTED N- (INDOL-2-CARBONYL) GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS
US5952294A (en) 1996-07-31 1999-09-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptidyl prodrugs and methods of making and using the same
FR2763337B1 (en) * 1997-05-13 1999-08-20 Sanofi Sa NOVEL TRIAZOLE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO2000024392A1 (en) 1998-10-26 2000-05-04 Sumitomo Pharmaceuticals Company, Limited β-AMYLOID FORMATION INHIBITORS
AU2847200A (en) * 1999-01-27 2000-08-18 G.D. Searle & Co. Novel hydroxyamidino carboxylate derivatives useful as nitric oxide synthase inhibitors
CN1436175A (en) * 2000-04-03 2003-08-13 布里斯托尔-迈尔斯斯奎布药品公司 Cyclic lactams as inhibitors of A beta-protein production
EP1335914A1 (en) * 2000-10-26 2003-08-20 Sanofi-Synthelabo Triazole derivatives and pharmaceutical compositions comprising them
CA2448737C (en) * 2001-07-20 2010-06-01 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
TW200303742A (en) 2001-11-21 2003-09-16 Novartis Ag Organic compounds
WO2008011131A2 (en) * 2006-07-21 2008-01-24 Takeda Pharmaceutical Company Limited Amide compounds
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
JP4164645B2 (en) 2002-08-09 2008-10-15 株式会社大塚製薬工場 DGAT inhibitor
MXPA05003432A (en) 2002-10-09 2005-07-05 Pfizer Prod Inc Pyrazole compounds for treatment of neurodegenerative disorders.
JP2006504796A (en) 2002-10-09 2006-02-09 ファイザー・プロダクツ・インク Thiazole compounds for treating neurodegenerative disorders
ATE482747T1 (en) * 2003-04-11 2010-10-15 High Point Pharmaceuticals Llc NEW AMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USES
CA2525764C (en) 2003-05-20 2012-07-17 Novartis Ag N-acyl nitrogen heterocycles as ligands of peroxisome proliferator-activated receptors
AR049333A1 (en) * 2004-04-02 2006-07-19 Vertex Pharma INHIBITING AZAINDOLS OF ROCK PROTEINQUINASES AND OTHER KINASE PROTEINS. PHARMACEUTICAL COMPOSITIONS.
US7402704B2 (en) 2004-04-14 2008-07-22 Amgen Inc. Arylsulfones and uses related thereto
JP2006089485A (en) * 2004-08-24 2006-04-06 Santen Pharmaceut Co Ltd Novel heterocyclic amide derivatives having dihydroorotate dehydrogenase inhibitory activity
JP4819686B2 (en) 2004-09-24 2011-11-24 ミドリ安全株式会社 Soles and shoes
DE102004047840A1 (en) 2004-09-29 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel substituted thiophenecarboxamides, their preparation and their use as pharmaceuticals
FR2876692B1 (en) 2004-10-19 2007-02-23 Sanofi Aventis Sa 2-AMIDO-4-PHENYLTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
TWI360539B (en) 2004-10-28 2012-03-21 Shionogi & Co 3-carbamoyl-2-pyridone derivatives
WO2006082952A1 (en) 2005-02-01 2006-08-10 Takeda Pharmaceutical Company Limited Amide compound
JP2008540485A (en) * 2005-05-10 2008-11-20 エフ．ホフマン−ラ ロシュ アーゲー Diacylglycerol acyltransferase inhibitor
WO2006127550A1 (en) * 2005-05-23 2006-11-30 Merck & Co., Inc. Proline bis-amide orexin receptor antagonists
AR055203A1 (en) * 2005-08-31 2007-08-08 Otsuka Pharma Co Ltd BENZOTIOPHENE DERIVATIVES WITH ANTIPSYTICAL PROPERTIES
EP2007716A1 (en) * 2006-04-13 2008-12-31 Glaxo Group Limited Aryl and heteroaryl sulphonamides as growth hormone secretagogue receptor agonists
TW200827340A (en) * 2006-11-10 2008-07-01 Astrazeneca Ab Chemical compounds
JP2008133218A (en) * 2006-11-28 2008-06-12 Hokko Chem Ind Co Ltd Phenoxybutyric acid amide derivatives and herbicides
US8957063B2 (en) 2008-02-21 2015-02-17 Boehringer Ingelheim International Gmbh Amine and ether compounds which modulate the CB2 receptor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005206492A (en) * 2004-01-21 2005-08-04 Sankyo Co Ltd Sulfonamide compound
US20070123504A1 (en) * 2005-11-28 2007-05-31 Bolin David R Diacylglycerol acyltransferase inhibitors

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002551366, retrieved from STN Database accession no. 669724-17-8 (RN) *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002551367, retrieved from STN Database accession no. 406470-01-7 (RN) *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002551368, retrieved from STN Database accession no. 402769-98-6 (RN) *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002551369, retrieved from STN Database accession no. 352565-18-5 (RN) *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002551370, retrieved from STN Database accession no. 329904-51-0 (RN) *
SHARMA S K ET AL: "Development of peptidomimetics targeting IAPs", INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS, vol. 12, no. 1, 1 January 2006 (2006-01-01), SPRINGER-VERLAG, DORDRECHT, NL, pages 21 - 32, XP002402669, ISSN: 1573-3149 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11014910B2 (en) 2018-03-01 2021-05-25 Japan Tobacco Inc. Methyllactam ring compound and pharmaceutical use thereof
US10988462B2 (en) 2018-04-04 2021-04-27 Japan Tobacco Inc. Pyrazole compounds substituted with heteroaryl and pharmaceutical use thereof

Also Published As

Publication number Publication date
CO6341581A2 (en) 2011-11-21
PE20110105A1 (en) 2011-02-25
US20100022513A1 (en) 2010-01-28
SV2011003809A (en) 2011-07-05
JP2011528016A (en) 2011-11-10
MX2011000628A (en) 2011-02-25
US8703761B2 (en) 2014-04-22
EP2559455A1 (en) 2013-02-20
BRPI0916216A2 (en) 2018-03-13
CR20110013A (en) 2011-02-11
CN102119047A (en) 2011-07-06
IL210292A0 (en) 2011-03-31
EP2548618A3 (en) 2013-02-27
EP2548618A2 (en) 2013-01-23
WO2010007046A2 (en) 2010-01-21
CA2731097A1 (en) 2010-01-21
NZ590285A (en) 2012-10-26
TW201006832A (en) 2010-02-16
AU2009272826A1 (en) 2010-01-21
CN102119047B (en) 2014-09-24
EP2349484A2 (en) 2011-08-03
CL2011000087A1 (en) 2011-07-01
JP5401544B2 (en) 2014-01-29
ECSP11010830A (en) 2011-03-31
MA32558B1 (en) 2011-08-01
EA201100189A1 (en) 2011-08-30
EP2380631A1 (en) 2011-10-26
AR072559A1 (en) 2010-09-08
UY31986A (en) 2010-02-26
KR20110028661A (en) 2011-03-21

Similar Documents

Publication Publication Date Title
WO2010007046A3 (en) Heteroaryl derivatives as dgat1 inhibitors
WO2008064018A8 (en) Thienopyrimidinones for treatment of inflammatory disorders and cancers
NZ594854A (en) Low-molecular polysulfated hyaluronic acid derivative and medicine containing same
WO2008075172A3 (en) Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
NZ594413A (en) Benzoic acid (1-phenyl-2-pyridin-4-yl) ethyl esters as phosphodiesterase inhibitors
WO2010008847A3 (en) Pi3k/m tor inhibitors
UA99882C2 (en) Benzofuranyl derivatives, pharmaceutical composition and method for the treatment of diseases
WO2009079008A8 (en) Benzopyrans and analogs as rho kinase inhibitors
MY150596A (en) Hsp90 inhibitors
WO2008086188A3 (en) Thiophene carboxamides as factor xa inhibitors
WO2008086226A8 (en) Factor xa inhibitors
MX2009003834A (en) Pyrrolydine derivatives as iap inhibitors.
MA33838B1 (en) Amorphous and crystalline form of the metrons of Keynes 112638 as a cloxylsramide synthetase inhibitor
EA201100503A1 (en) GLUCOSIDE DERIVATIVES AND THEIR APPLICATIONS
WO2009023539A3 (en) Tetrahydropyridine carboxamide derivatives as trpvl antagonists
PH12014502413A1 (en) Cyclic bridgehead ether dgat1 inhibitors
UA105786C2 (en) Amine addition salts containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as dhodh innhibitors
WO2008036652A3 (en) Amidines as modulators of indoleamine 2,3-dioxygenase
NO20085212L (en) New pyridine analogs
MX2008010884A (en) 4-phenyl-thiazole-5-carboxylic acids and 4-phenyl-thiazole-5-carb oxylic acid amides as plk1 inhibitors.
GEP20115166B (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
MY150774A (en) Isoquinoline derivative
WO2013062964A3 (en) Methanol derivatives as trpv3 modulators
WO2007137098A3 (en) Sulfonyl-substituted bicyclic compounds as modulators of ppar
WO2010056585A3 (en) Heteroaryl diamide compounds useful as mmp-13 inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980131154.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09780542

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009272826

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 210292

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 590285

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 168/DELNP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: CR2011-000013

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 2011010072

Country of ref document: EG

Ref document number: 12011500082

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 2011517900

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2011000087

Country of ref document: CL

Ref document number: 2731097

Country of ref document: CA

Ref document number: 000039-2011

Country of ref document: PE

Ref document number: MX/A/2011/000628

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: D2011012

Country of ref document: CU

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009780542

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009272826

Country of ref document: AU

Date of ref document: 20090714

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201100189

Country of ref document: EA

Ref document number: DZP2011000119

Country of ref document: DZ

ENP Entry into the national phase

Ref document number: 20117003370

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 11019986

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: A201101617

Country of ref document: UA

ENP Entry into the national phase

Ref document number: PI0916216

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110117